Clinical Trials Browser

Recruiting × Epirubicin × 1 year × Clear all

NCT06966700 2026-04-17

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07441460 2026-04-08

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

Phase 3 Recruiting

Resectable HER2-positive Breast Cancer

NCT06797635 2026-03-13

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Phase 2 Recruiting

Breast Neoplasms

NCT06291064 2026-02-17

TARMAC

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT07320508 2026-01-21

EIC-SNACC

Phase 2 Recruiting

Carcinoma, Adenoid Cystic

NCT06107673 2025-12-11

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

Phase 2 Recruiting

Breast Neoplasms

NCT06421948 2025-12-05

Linperlisib Combined With Chidamide in Patients With PTCL

Phase 1/2 Recruiting

Lymphoma, T-Cell, Peripheral

NCT07016399 2025-10-30

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT04138719 2025-09-11

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05900206 2025-09-02

ARIADNE

Phase 2 Recruiting

Breast Neoplasms

NCT05582499 2025-08-22

FASCINATE-N

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05862064 2025-07-16

A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT06500208 2025-06-26

Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC

Phase 2 Recruiting

Breast Neoplasms

NCT06860529 2025-06-23

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

Phase 2 Recruiting

HR+/HER2- Breast Cancer

NCT06964906 2025-05-11

NeoHunter

Phase 2 Recruiting

Breast Neoplasms